To further investigate the effect of CSGALNACT2 expression on ovarian cancer prognosis under different immune cell-enriched or decreased conditions, we performed a survival analysis of ovarian cancer patients in the TCGA cohort. The gene discussed is CSGALNACT2; the disease is ovarian carcinoma.